Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Advanced Proteome Therapeutics Corporation V.APC.H

Alternate Symbol(s):  APTCF

Healthcare Biotechnology
Advanced Proteome Therapeutics Corporation is actively seeking additional funds to advance its core technologies for partnering and other potential revenue streams. It is not engaged in any activity.


TSXV:APC.H - Post by User

Advanced Proteome Therapeutics Corporation
Bullboard Posts
User Avatar Image
(0)
•••
Post by Trader8on Apr 07, 2018 3:50pm
103 Views
Post# 27847975

Stock options granted.....News usually follows...

Stock options granted.....News usually follows...Advanced Proteome Therapeutics Announces Stock Option Grants Vancouver, British Columbia / April 6, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) announces that it has granted incentive stock options to purchase a total of 1,630,000 common shares at an exercise price of $0.065 per share for a period of two years to its directors, officers and consultants in accordance with the provisions of its stock option plan.

https://www.sedar.com/GetFile.do?lang=EN&docClass=8&issuerNo=00024485&issuerType=03&projectNo=02754812&docId=4292607
Consultants are accepting shares for pay...Always a good sign...We will be getting news soon.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities